echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > New Lancet research shows that ordinary antidepressants should no longer be used to treat patients with dementia

    New Lancet research shows that ordinary antidepressants should no longer be used to treat patients with dementia

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to a new study, a drug used to treat agitation in patients with dementia is not more effective than a placebo and may even increase mortality


    The study, led by the University of Plymouth and published in The Lancet, showed that the antidepressant mirtazapine has no effect on anxiety in patients with dementia and may be more likely to be associated with mortality than no intervention at all


    Restlessness is a common symptom of dementia, which is characterized by inappropriate speech, sound or motor activities, often involving physical and verbal aggression


    This study was funded by the National Institutes of Health (NIHR) and recruited 204 people who may or may have Alzheimer's disease from 20 places in the UK.


    The results showed that after 12 weeks, the mirtazapine group had no less agitation than the control group


    The lead researcher, Executive Dean of the University of Plymouth School of Health and Professor Sube Banerjee, professor of dementia, explained why these results are so surprising but important


    There are 46 million people living with dementia worldwide, and this number will double in the next 20 years


    "This study shows that common symptom management methods are not helpful and may even be harmful


    "This study adds important information to the evidence base, and we look forward to further research on treatments that can help improve people's quality of life


    Article title

    Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.